Loncastuximab Tesirine

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: July 31, 2026

Investigation of Payloads and Related Impurities in the cysteine-linked Antibody-Drug Conjugate Using Mass Spectrometry Techniques.

Investigation of Payloads and Related Impurities in the cysteine-linked Antibody-Drug Conjugate Using Mass Spectrometry Techniques.

Journal: Applied biochemistry and biotechnology

Published: July 04, 2026

Persistent Diffuse Telangiectatic Eruption Associated With Loncastuximab Tesirine.

Persistent Diffuse Telangiectatic Eruption Associated With Loncastuximab Tesirine.

Journal: The American Journal of dermatopathology

Published: June 26, 2026

Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.

Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.

Journal: Cancer

Published: March 01, 2026

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience.

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience.

Journal: European journal of haematology

Published: February 23, 2026

Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report.

Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report.

Journal: Annals of hematology

Published: February 05, 2026

Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.

Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.

Journal: European journal of haematology

Published: January 28, 2026

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL.

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL.

Journal: Blood reviews

Published: November 27, 2025

Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Journal: Systematic reviews

Published: November 09, 2025

Antibody-drug conjugates in hematologic malignancies.

Antibody-drug conjugates in hematologic malignancies.

Journal: Cancer

Published: October 08, 2025

Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

Journal: Seminars in hematology

Published: September 17, 2025

Therapeutic monoclonal antibodies repurposing in oncology via IMGT/mAb-KG embeddings.

Therapeutic monoclonal antibodies repurposing in oncology via IMGT/mAb-KG embeddings.

Journal: BMC medical informatics and decision making

Published: August 08, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026